Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Antiviral Res ; 227: 105876, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38641023

ABSTRACT

BACKGROUND: HBeAg loss is an important endpoint for antiviral therapy in chronic hepatitis B (CHB), however there are no reliable biomarkers to identify patients who will respond to the addition of pegylated interferon to nucleos(t)ide analogue (NA) therapy. AIM: To evaluate the use of serum biomarkers to predict HBeAg loss. METHODS: HBeAg positive CHB participants on NAs who switched-to or added-on 48 weeks pegylated interferon alpha2b (clinicaltrial.gov NCT01928511) were evaluated at week 72 for HBeAg loss. The predictive ability of qHBeAg, qHBsAg, HBV RNA and clinical variables for HBeAg loss were investigated. RESULTS: HBeAg loss occurred in 15/55 (27.3%) participants who completed 48 weeks of pegylated interferon. There was a lower baseline qHBeAg (1.18 IU/mL [2.27] versus 10.04 IU/mL [24.87], P = 0.007) among participants who lost HBeAg. Baseline qHBeAg (OR = 0.15, 95% CI 0.03-0.66, P = 0.01) and detectable HBV DNA at baseline (OR = 25.00, 95% CI 1.67-374.70, P = 0.02) were independent predictors of HBeAg loss. In addition, on-treatment qHBeAg was also a strong predictor of HBeAg loss (OR = 0.39, 95% CI 0.18-0.81, P = 0.012). The models combining detectable baseline HBV DNA with baseline (C-statistic 0.82) and on-treatment (C-statistic 0.83) had good accuracy for predicting HBeAg loss. A rise in qHBeAg ≥ 10 IU/ml was a predictor of flare (ALT ≥ 120 U/ml) on univariable analysis but not after adjustment for treatment arm. CONCLUSIONS: Baseline and on-treatment qHBeAg is a useful biomarker that can identify participants on NA therapy who may benefit from adding or switching to pegylated interferon.


Subject(s)
Antiviral Agents , Biomarkers , Hepatitis B e Antigens , Hepatitis B, Chronic , Interferon-alpha , Polyethylene Glycols , Recombinant Proteins , Adult , Female , Humans , Male , Middle Aged , Young Adult , Antiviral Agents/therapeutic use , Biomarkers/blood , DNA, Viral/blood , Drug Therapy, Combination , Hepatitis B e Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/drug effects , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/virology , Interferon alpha-2/therapeutic use , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Recombinant Proteins/therapeutic use , Treatment Outcome
2.
Virol J ; 18(1): 235, 2021 11 29.
Article in English | MEDLINE | ID: mdl-34844619

ABSTRACT

BACKGROUND: Hepatitis B virus (HBV) serum markers during typical acute self-limited infection are usually depicted as a composite of traditional HBV markers. The current study updates and expands our knowledge of acute hepatitis B with quantitative molecular and serological data on longitudinal samples from five plasmapheresis donors with acute HBV. METHODS: 137 longitudinal samples from five plasmapheresis donors with acute HBV were tested, four with self-limited infection and one who developed persistent infection. Testing included quantitative hepatitis B surface antigen (HBsAg), antibodies to HBV antigens, quantitative HBV e antigen (HBeAg), HBV DNA, quantitative HBV core-related antigen (HBcrAg), the highly sensitive ARCHITECT HBsAg NEXT (HBsAgNx) assay, and a quantitative research assay for HBV pregenomic RNA (pg RNA). RESULTS: Peak levels of HBV DNA and HBsAg differed by several orders of magnitude among the panels (2.2 × 105-2.7 × 109 IU/ml for HBV DNA and 7.9-1.1 × 105 IU/ml for HBsAg). HBsAg levels peaked an average of 2.8 days after the HBV DNA peak. The overall duration of observed HBsAg positivity was increased by the more sensitive HBsAgNx assay compared to the quantitative assay in four panels. Intermittently detectable low-level HBV DNA was observed after HBsAg loss in three panels. Peak HBeAg levels occurred 2-20 days after the DNA peak and ranged from 1.1 to 4.5 × 103 IU/ml. In four panels with resolution of infection, anti-HBs levels indicating immunity (≥ 10 mIU/ml) were detected 19-317 days after the HBV DNA peak. Maximum HBcrAg concentrations ranged from 1 × 105 to > 6.4 × 106 U/ml and correlated with HBeAg values (R2 = 0.9495) and with HBV DNA values (R2 = 0.8828). Peak pgRNA values ranged from 1.6 × 103 to 1.4 × 108 U/ml and correlated with HBV DNA (R2 = 0.9013). CONCLUSION: Traditional and new/novel HBV biomarkers were used to generate molecular and serological profiles for seroconversion panels spanning the early to late phases of acute HBV. Seroconversion profiles were heterogeneous and may be instructive in appreciating the spectrum of acute profiles relative to the typical composite representation.


Subject(s)
Hepatitis B, Chronic , Hepatitis B , Biomarkers , DNA, Viral/genetics , Hepatitis B Core Antigens , Hepatitis B Surface Antigens , Hepatitis B e Antigens , Hepatitis B virus/genetics , Humans , Seroconversion
3.
Viruses ; 13(10)2021 10 13.
Article in English | MEDLINE | ID: mdl-34696483

ABSTRACT

BACKGROUND: Gaps remain in the detection of nucleic acid test (NAT) yield and occult hepatitis B virus (HBV) infection (OBI) by current HBV surface antigen (HBsAg) assays. The lack of detection may be due to HBsAg levels below current assay detection limits, mutations affecting HBsAg assays or HBsAg levels, or the masking of HBsAg by antibody to HBsAg (anti-HBs). In this study, we evaluate the incremental detection of NAT yield and OBI from five diverse geographic areas by an improved sensitivity HBsAg assay and characterize the samples relative to the viral load, anti-HBs status, and PreS1-S2-S mutations. Included is a comparison population with HBV DNA levels comparable to OBI, but with readily detectable HBsAg (High Surface-Low DNA, HSLD). METHODS: A total of 347 samples collected from the USA, South Africa, Spain, Cameroon, Vietnam, and Cote D'Ivoire representing NAT yield (HBsAg(-), antibody to HBV core antigen (anti-HBc)(-), HBV DNA(+), N = 131), OBI (HBsAg(-), anti-HBc(+), HBV DNA(+), N = 188), and HSLD (HBsAg(+), anti-HBc(+), HBV DNA(+), N = 28) were tested with ARCHITECT HBsAg NEXT (HBsAgNx) (sensitivity 0.005 IU/mL). The sequencing of the PreS1-S2-S genes from a subset of 177 samples was performed to determine the genotype and assess amino acid variability, particularly in anti-HBs(+) samples. RESULTS: HBsAgNx detected 44/131 (33.6%) NAT yield and 42/188 (22.3%) OBI samples. Mean HBV DNA levels for NAT yield and OBI samples were lower in HBsAgNx(-) (50.3 and 25.9 IU/mL) than in HBsAgNx(+) samples (384.1 and 139.5 IU/mL). Anti-HBs ≥ 10 mIU/mL was present in 28.6% HBsAgNx(+) and 45.2% HBsAgNx(-) OBI, and in 3.6% HSLD samples. The genotypes were A1, A2, B, C, D, E, F, and H. There was no significant difference between HBsAgNx(-) and HBsAgNx(+) in the proportion of samples harboring substitutions or in the mean number of substitutions per sample in PreS1, PreS2, or S for the NAT yield or OBI (p range: 0.1231 to >0.9999). A total of 21/27 (77.8%) of HBsAgNx(+) OBI carried S escape mutations, insertions, or stop codons. HSLD had more PreS1 and fewer S substitutions compared to both HBsAgNx(-) and HBsAgNx(+) OBI. Mutations/deletions associated with impaired HBsAg secretion were observed in the OBI group. CONCLUSIONS: HBsAgNx provides the improved detection of NAT yield and OBI samples. Samples that remain undetected by HBsAgNx have exceptionally low HBsAg levels below the assay detection limit, likely due to low viremia or the suppression of HBsAg expression by host and viral factors.


Subject(s)
Hepatitis B Surface Antigens/metabolism , Hepatitis B virus/genetics , Hepatitis B/diagnosis , Antigens, Surface/genetics , Cameroon , Cote d'Ivoire , DNA, Viral/genetics , Diagnostic Tests, Routine , Genotype , Hepatitis B/genetics , Hepatitis B/metabolism , Hepatitis B Antibodies/immunology , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/blood , Hepatitis B Surface Antigens/genetics , Hepatitis B virus/metabolism , Humans , Limit of Detection , Mutation/genetics , Protein Precursors/genetics , Sensitivity and Specificity , Serologic Tests , South Africa , Spain , United States , Vietnam , Viral Load
4.
Endocrinology ; 162(4)2021 04 01.
Article in English | MEDLINE | ID: mdl-33388754

ABSTRACT

Gene transcription occurs in short bursts interspersed with silent periods, and these kinetics can be altered by promoter structure. The effect of alternate promoter architecture on transcription bursting is not known. We studied the human prolactin (hPRL) gene that contains 2 promoters, a pituitary-specific promoter that requires the transcription factor Pit-1 and displays dramatic transcriptional bursting activity and an alternate upstream promoter that is active in nonpituitary tissues. We studied large hPRL genomic fragments with luciferase reporters, and used bacterial artificial chromosome recombineering to manipulate critical promoter regions. Stochastic switch mathematical modelling of single-cell time-lapse luminescence image data revealed that the Pit-1-dependent promoter showed longer, higher-amplitude transcriptional bursts. Knockdown studies confirmed that the presence of Pit-1 stabilized and prolonged periods of active transcription. Pit-1 therefore plays an active role in establishing the timing of transcription cycles, in addition to its cell-specific functions.


Subject(s)
Prolactin/genetics , Promoter Regions, Genetic , Transcription Factor Pit-1/metabolism , Transcription, Genetic , Cell Line , Gene Expression Regulation , Humans , Pituitary Gland/metabolism , Prolactin/metabolism , Transcription Factor Pit-1/genetics
5.
Aliment Pharmacol Ther ; 53(1): 172-182, 2021 01.
Article in English | MEDLINE | ID: mdl-33159496

ABSTRACT

BACKGROUND: Biomarkers such as quantitative HBsAg (qHBsAg), quantitative hepatitis B virus (HBV) core-related antigen (qHBcrAg) and HBV RNA may be useful in predicting HBsAg loss in patients with chronic hepatitis B (CHB) undergoing antiviral therapy. AIM(S): Our study evaluated qHBsAg, HBV RNA and qHBcrAg as a posthoc analysis of a randomized clinical trial of peginterferon±NA to determine their utility in predicting HBsAg loss. METHODS: CHB patients who completed therapy with 48weeks peginterferon alpha2b ± nucleoside analogue therapy (clinicaltrial.gov NCT01928511) were evaluated at week 72 for HBsAg loss. The predictive ability of qHBsAg, qHBcrAg, HBV RNA and other variables were investigated by univariate and multivariate logistic models for HBeAg-negative patients by odds ratios, area under the curve (AUC), sensitivity, specificity, and positive and negative likelihood ratios (LR). RESULTS: HBsAg loss occurred in 15/114(13%) HBeAg-negative CHB patients who completed 48 weeks of peginterferon. At baseline, qHBsAg was superior to HBcrAg and HBV RNA with AUC 0.916, 0.649 and 0.542, respectively. Using multivariate analysis, the model comprising treatmentarm, age, gender, baseline qHBsAg, HBcrAg and HBV RNA, weeks 4 & 8 qHBsAg had the highest AUC(0.98), but the univariate model with week 8 qHBsAg <70 IU/mL had AUC 0.96. Hence, the contributions of variables other than qHBsAg were marginal. HBV RNA and qHBcrAg were weak predictors of HBsAg loss. Kinetics of the novel markers showed only qHBsAg had a good relationship with HBsAg loss while HBV RNA had a marginal relationship and HBcrAg did not change at all, and none had a good relationship with viral rebound. CONCLUSIONS: On-treatment biomarker predictors were better than baseline ones, and the best predictor of HBsAg loss at 72 weeks was week 8 qHBsAg <70 IU/mL.


Subject(s)
Antiviral Agents , Hepatitis B, Chronic , Antiviral Agents/therapeutic use , Biomarkers , DNA, Viral , Hepatitis B Surface Antigens , Hepatitis B e Antigens , Hepatitis B virus/genetics , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/drug therapy , Humans
6.
J Mol Endocrinol ; 66(1): 59-69, 2021 01.
Article in English | MEDLINE | ID: mdl-33112804

ABSTRACT

Pituitary cells have been reported to show spontaneous calcium oscillations and dynamic transcription cycles. To study both processes in the same living cell in real time, we used rat pituitary GH3 cells stably expressing human prolactin-luciferase or prolactin-EGFP reporter gene constructs loaded with a fluorescent calcium indicator and measured activity using single-cell time-lapse microscopy. We observed heterogeneity between clonal cells in the calcium activity and prolactin transcription in unstimulated conditions. There was a significant correlation between cells displaying spontaneous calcium spikes and cells showing spontaneous bursts in prolactin expression. Notably, cells showing no basal calcium activity showed low prolactin expression but elicited a significantly greater transcriptional response to BayK8644 compared to cells showing basal calcium activity. This suggested the presence of two subsets of cells within the population at any one time. Fluorescence-activated cell sorting was used to sort cells into two populations based on the expression level of prolactin-EGFP however, the bimodal pattern of expression was restored within 26 h. Chromatin immunoprecipitation showed that these sorted populations were distinct due to the extent of histone acetylation. We suggest that maintenance of a heterogeneous bimodal population is a fundamental characteristic of this cell type and that calcium activation and histone acetylation, at least in part, drive prolactin transcriptional competence.


Subject(s)
Calcium/metabolism , Chromatin Assembly and Disassembly , Genetic Heterogeneity , Prolactin/genetics , Transcription, Genetic , Acetylation , Animals , Cell Line , Histones/metabolism , Prolactin/metabolism , Rats , Single-Cell Analysis
8.
J Clin Virol ; 118: 41-45, 2019 09.
Article in English | MEDLINE | ID: mdl-31442662

ABSTRACT

BACKGROUND: Hepatitis B surface antigen (HBsAg) is the primary marker for diagnosis of acute and chronic hepatitis B. Although HBsAg assays have undergone continuous improvement, gaps remain in the detection of early and late acute infection and occult hepatitis B infection (OBI). OBJECTIVES: The performance of a prototype, improved sensitivity HBsAg assay run on the ARCHITECT and Alinity instruments was evaluated for detection of early and late acute infection and OBI. STUDY DESIGN: Seventy seven early acute samples [positive only for hepatitis B viral DNA (HBV DNA)], twelve seroconversion panels spanning late acute infection, and 101 occult samples (HBsAg negative, positive for HBV DNA and anti-HBc) were tested with the prototype assay and ARCHITECT HBsAg Qualitative II. HBsAg gene sequencing was performed to determine genotype and mutations in the immunodominant region. RESULTS: Compared with ARCHITECT HBsAg Qualitative II, the prototype assay showed increased detection of NAT yield samples (28/77, 36.4%,), late acute samples (≥13 days longer detection of HBsAg for 6/12 panels), and OBI samples (11/101, 10.9%). HBsAg sequence data were obtained for 62 samples. Genotypes represented were A1, A2, B2, B4, C1, C2, C5, D3, E, and H. HBsAg escape mutations were found in 4.8% of NAT yield and 38.9% of OBI samples sequenced. Prototype assay values for 188 samples were equivalent on the ARCHITECT and Alinity instruments. CONCLUSIONS: The new prototype HBsAg assay will be of diagnostic value in providing improved detection of early acute, late acute, and occult HBV infections.


Subject(s)
Biomarkers/blood , Diagnostic Tests, Routine/methods , Hepatitis B Surface Antigens/blood , Hepatitis B/diagnosis , DNA, Viral/chemistry , DNA, Viral/genetics , Genotype , Hepatitis B Surface Antigens/genetics , Humans , Sensitivity and Specificity , Sequence Analysis, DNA
9.
PLoS Comput Biol ; 15(6): e1007030, 2019 06.
Article in English | MEDLINE | ID: mdl-31194728

ABSTRACT

Prolactin is a major hormone product of the pituitary gland, the central endocrine regulator. Despite its physiological importance, the cell-level mechanisms of prolactin production are not well understood. Having significantly improved the resolution of real-time-single-cell-GFP-imaging, the authors recently revealed that prolactin gene transcription is highly dynamic and stochastic yet shows space-time coordination in an intact tissue slice. However, it still remains an open question as to what kind of cellular communication mediates the observed space-time organization. To determine the type of interaction between cells we developed a statistical model. The degree of similarity between two expression time series was studied in terms of two distance measures, Euclidean and geodesic, the latter being a network-theoretic distance defined to be the minimal number of edges between nodes, and this was used to discriminate between juxtacrine from paracrine signalling. The analysis presented here suggests that juxtacrine signalling dominates. To further determine whether the coupling is coordinating transcription or post-transcriptional activities we used stochastic switch modelling to infer the transcriptional profiles of cells and estimated their similarity measures to deduce that their spatial cellular coordination involves coupling of transcription via juxtacrine signalling. We developed a computational model that involves an inter-cell juxtacrine coupling, yielding simulation results that show space-time coordination in the transcription level that is in agreement with the above analysis. The developed model is expected to serve as the prototype for the further study of tissue-level organised gene expression for epigenetically regulated genes, such as prolactin.


Subject(s)
Cell Communication/genetics , Models, Biological , Paracrine Communication/genetics , Animals , Cell Communication/physiology , Computational Biology , Gene Expression Regulation/genetics , Humans , Male , Paracrine Communication/physiology , Pituitary Gland/metabolism , Prolactin/genetics , Prolactin/metabolism , Rats , Rats, Transgenic , Stochastic Processes
10.
Virol J ; 16(1): 43, 2019 04 03.
Article in English | MEDLINE | ID: mdl-30943997

ABSTRACT

BACKGROUND: Although vaccines for hepatitis B virus (HBV) are highly effective, HBV infections in vaccinees occur. Index samples of breakthrough infections are typically anti-HBc negative but HBV DNA positive with protective anti-HBs levels while HBsAg detection may be delayed or absent. HBsAg mutations have been associated with some vaccine breakthrough cases. METHODS: This research characterizes the serological and molecular profiles of vaccine breakthrough infections in serial samples from two commercially available plasma donor panels. Samples were tested with commercially available assays for HBV antigens and antibodies: HBsAg, HBeAg, anti-HBc, anti-HBc IgM, anti-HBe, and anti-HBs. Different immunoassay approaches for earlier detection of breakthrough infection were explored including hepatitis B core-related antigen (HBcrAg), a research assay for preS2 antigen, and a new prototype ARCHITECT HBsAg assay with improved sensitivity. The prototype HBsAg assay is fully automated and involves no sample pre-treatment. Molecular testing included HBV DNA quantitation and sequencing of preS1, preS2, surface, and basal core promoter/core promoter genes. RESULTS: Although the research preS2 antigen assay allowed earlier detection of the breakthrough infections than current HBsAg assays and HBcrAg, the new prototype ARCHITECT HBsAg assay provided the earliest serologic detection. The ability of the new prototype HBsAg assay to detect HBsAg in the presence of anti-HBs was investigated using known concentrations of native HBsAg mixed with anti-HBs from a vaccinee. The results demonstrated that the prototype ARCHITECT assay is more sensitive in detecting HBsAg in the presence of anti-HBs than current HBsAg assays. Sequencing revealed multiple substitutions in preS1, preS2, and S regions for one panel including a rare D144N substitution associated with vaccine breakthrough that emerged with increasing frequency as the breakthrough infection developed. CONCLUSIONS: When compared with other immunoassay approaches, the new prototype ARCHITECT HBsAg assay allows earlier detection of vaccine breakthrough infections and more sensitive detection of HBsAg in the presence of anti-HBs. Molecular characterization of longitudinal samples demonstrated the progressive appearance of a rare HBsAg mutation associated with vaccine breakthrough.


Subject(s)
Blood Donors , Hepatitis B Surface Antigens/genetics , Hepatitis B Vaccines/therapeutic use , Hepatitis B/diagnosis , Serologic Tests , Automation, Laboratory , DNA, Viral/analysis , Hepatitis B Antibodies/blood , Hepatitis B Core Antigens/blood , Hepatitis B Core Antigens/genetics , Hepatitis B Surface Antigens/blood , Hepatitis B Vaccines/administration & dosage , Hepatitis B e Antigens/blood , Hepatitis B e Antigens/genetics , Hepatitis B virus/genetics , Humans , Immunoassay , Mutation , Sensitivity and Specificity
11.
Hepatology ; 68(6): 2106-2117, 2018 12.
Article in English | MEDLINE | ID: mdl-29734472

ABSTRACT

Treatment of chronic hepatitis B (CHB) patients with nucleos(t)ide analogs (NAs) suppresses hepatitis B virus (HBV) DNA synthesis but does not affect synthesis of HBV pregenomic RNA (pgRNA). Hepatitis B virus pgRNA is detectable in the serum during NA treatment and has been proposed as a marker of HBV covalently closed circular DNA activity within the infected hepatocyte. We developed an automated assay for the quantification of serum HBV pgRNA using a dual-target real-time quantitative PCR approach on the Abbott m2000sp/rt system. We demonstrate accurate detection and quantification of serum HBV RNA. Hepatitis B virus DNA was quantified using the Abbott RealTime HBV viral load assay. We further compared serum nucleic acid levels and kinetics in HBV-positive populations. Samples included on-therapy CHB samples (n = 16), samples (n = 89) from 10 treatment naïve CHB subjects receiving 12 weeks of NA treatment with 8-week follow-up, hepatitis B surface antigen-positive blood donor samples (n = 102), and three seroconversion series from plasmapheresis donors (n = 79 samples). Conclusion: During NA treatment of CHB subjects, we observed low correlation of HBV DNA to pgRNA levels; pgRNA concentration was generally higher than HBV DNA concentrations. In contrast, when NA treatment was absent we observed serum pgRNA at concentrations that correlated to HBV DNA and were approximately 2 log lower than HBV DNA. Importantly, we observe this trend in untreated subject samples from both chronic infections and throughout seroconversion during acute infection. Results demonstrate that the presence of pgRNA in serum is part of the HBV lifecycle; constant relative detection of pgRNA and HBV DNA in the serum is suggestive of a linked mechanism for egress for HBV DNA or pgRNA containing virions.


Subject(s)
DNA, Viral/blood , Hepatitis B/blood , Lamivudine/therapeutic use , Nucleosides/therapeutic use , RNA, Viral/blood , Biomarkers/blood , Hepatitis B/drug therapy , Hepatitis B/virology , Humans , Viral Load
12.
Sci Rep ; 8(1): 2095, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29391553

ABSTRACT

Worldwide, an estimated 5% of hepatitis B virus (HBV) infected people are coinfected with hepatitis delta virus (HDV). HDV infection leads to increased mortality over HBV mono-infection, yet HDV diagnostics are not widely available. Prototype molecular (RNA) and serologic (IgG) assays were developed for high-throughput testing on the Abbott m2000 and ARCHITECT systems, respectively. RNA detection was achieved through amplification of a ribozyme region target, with a limit of detection of 5 IU/ml. The prototype serology assay (IgG) was developed using peptides derived from HDV large antigen (HDAg), and linear epitopes were further identified by peptide scan. Specificity of an HBV negative population was 100% for both assays. A panel of 145 HBsAg positive samples from Cameroon with unknown HDV status was tested using both assays: 16 (11.0%) had detectable HDV RNA, and 23 (15.7%) were sero-positive including the 16 HDV RNA positive samples. Additionally, an archival serial bleed panel from an HDV superinfected chimpanzee was tested with both prototypes; data was consistent with historic testing data using a commercial total anti-Delta test. Overall, the two prototype assays provide sensitive and specific methods for HDV detection using high throughput automated platforms, allowing opportunity for improved diagnosis of HDV infected patients.


Subject(s)
Antibodies, Viral/blood , Hepatitis B/diagnosis , Hepatitis Delta Virus/physiology , Hepatitis delta Antigens/blood , RNA, Viral/genetics , Serologic Tests/methods , Animals , Hepatitis B/blood , Hepatitis B/virology , Hepatitis delta Antigens/immunology , Pan troglodytes , Seroconversion
13.
Cell Syst ; 5(6): 646-653.e5, 2017 12 27.
Article in English | MEDLINE | ID: mdl-29153839

ABSTRACT

Transcription in eukaryotic cells occurs in gene-specific bursts or pulses of activity. Recent studies identified a spectrum of transcriptionally active "on-states," interspersed with periods of inactivity, but these "off-states" and the process of transcriptional deactivation are poorly understood. To examine what occurs during deactivation, we investigate the dynamics of switching between variable rates. We measured live single-cell expression of luciferase reporters from human growth hormone or human prolactin promoters in a pituitary cell line. Subsequently, we applied a statistical variable-rate model of transcription, validated by single-molecule FISH, to estimate switching between transcriptional rates. Under the assumption that transcription can switch to any rate at any time, we found that transcriptional activation occurs predominantly as a single switch, whereas deactivation occurs with graded, stepwise decreases in transcription rate. Experimentally altering cAMP signalling with forskolin or chromatin remodelling with histone deacetylase inhibitor modifies the duration of defined transcriptional states. Our findings reveal transcriptional activation and deactivation as mechanistically independent, asymmetrical processes.


Subject(s)
Human Growth Hormone/genetics , Models, Theoretical , Pituitary Gland/physiology , Prolactin/genetics , Transcription, Genetic , Animals , Cell Line , Cyclic AMP/metabolism , Female , Genes, Reporter/genetics , Histone Deacetylases/metabolism , Humans , Luciferases/genetics , Promoter Regions, Genetic/genetics , Rats , Single-Cell Analysis , Transcriptional Activation
14.
Elife ; 5: e08494, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26828110

ABSTRACT

Transcription at individual genes in single cells is often pulsatile and stochastic. A key question emerges regarding how this behaviour contributes to tissue phenotype, but it has been a challenge to quantitatively analyse this in living cells over time, as opposed to studying snap-shots of gene expression state. We have used imaging of reporter gene expression to track transcription in living pituitary tissue. We integrated live-cell imaging data with statistical modelling for quantitative real-time estimation of the timing of switching between transcriptional states across a whole tissue. Multiple levels of transcription rate were identified, indicating that gene expression is not a simple binary 'on-off' process. Immature tissue displayed shorter durations of high-expressing states than the adult. In adult pituitary tissue, direct cell contacts involving gap junctions allowed local spatial coordination of prolactin gene expression. Our findings identify how heterogeneous transcriptional dynamics of single cells may contribute to overall tissue behaviour.


Subject(s)
Gene Expression Regulation , Pituitary Gland/physiology , Transcription, Genetic , Animals , Gene Expression Profiling , Genes, Reporter , Optical Imaging , Rats, Inbred F344 , Spatio-Temporal Analysis
15.
Mol Endocrinol ; 30(2): 189-200, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26691151

ABSTRACT

The use of bacterial artificial chromosome (BAC) reporter constructs in molecular physiology enables the inclusion of large sections of flanking DNA, likely to contain regulatory elements and enhancers regions that contribute to the transcriptional output of a gene. Using BAC recombineering, we have manipulated a 160-kb human prolactin luciferase (hPRL-Luc) BAC construct and mutated the previously defined proximal estrogen response element (ERE) located -1189 bp relative to the transcription start site, to assess its involvement in the estrogen responsiveness of the entire hPRL locus. We found that GH3 cell lines stably expressing Luc under control of the ERE-mutated hPRL promoter (ERE-Mut) displayed a dramatically reduced transcriptional response to 17ß-estradiol (E2) treatment compared with cells expressing Luc from the wild-type (WT) ERE hPRL-Luc promoter (ERE-WT). The -1189 ERE controls not only the response to E2 treatment but also the acute transcriptional response to TNFα, which was abolished in ERE-Mut cells. ERE-WT cells displayed a biphasic transcriptional response after TNFα treatment, the acute phase of which was blocked after treatment with the estrogen receptor antagonist 4-hydroxy-tamoxifen. Unexpectedly, we show the oscillatory characteristics of hPRL promoter activity in individual living cells were unaffected by disruption of this crucial response element, real-time bioluminescence imaging showed that transcription cycles were maintained, with similar cycle lengths, in ERE-WT and ERE-Mut cells. These data suggest the -1189 ERE is the dominant response element involved in the hPRL transcriptional response to both E2 and TNFα and, crucially, that cycles of hPRL promoter activity are independent of estrogen receptor binding.


Subject(s)
Estrogens/genetics , Estrogens/pharmacology , Prolactin/genetics , Response Elements/genetics , Transcription, Genetic/drug effects , Base Sequence , Cell Line , Estradiol/pharmacology , Humans , Luciferases/metabolism , Molecular Sequence Data , Mutant Proteins/metabolism , Mutation/genetics , Protein Binding/drug effects , Receptors, Estrogen/metabolism , Time Factors , Tumor Necrosis Factor-alpha/pharmacology
16.
Nurs Adm Q ; 36(3): 253-9, 2012.
Article in English | MEDLINE | ID: mdl-22677966

ABSTRACT

The new world order demands nursing faculty members be as competent in teaching and coaching students as they are about the art and science of nursing. The complexity associated with classroom management requires mastery of innovative learning modalities to assist students to think critically using research-based evidence in making patient care decisions. Grand Canyon University has made faculty competence a priority to ensure quality student outcomes. The College of Nursing has embraced a systematic process for creating faculty excellence through a comprehensive faculty development initiative. Developing faculty requires university support through policy and resources that is essential to prepare nurses for the new world order and therefore closing the education practice gap.


Subject(s)
Clinical Competence , Education, Nursing/methods , Educational Status , Faculty, Nursing/standards , Schools, Nursing/standards , Staff Development/methods , Arizona , Cooperative Behavior , Diffusion of Innovation , Humans , Learning , Mentors , Students, Nursing , United States
17.
Endocrinology ; 153(6): 2724-34, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22495675

ABSTRACT

Prolactin (PRL) is mainly expressed in the pituitary in rodents, whereas in humans, expression is observed in many extrapituitary sites, including lymphocytes. Due to the lack of adequate experimental models, the function of locally produced PRL in the immune system is largely unknown. Using transgenic rats that express luciferase under the control of extensive human PRL regulatory regions, we characterized immune cell responses to thioglycollate (TG)-induced peritonitis. Resident populations of myeloid cells in the peritoneal cavity of untreated rats expressed barely detectable levels of luciferase. In contrast, during TG-induced peritonitis, cell-specific expression in both neutrophils and monocytes/macrophages in peritoneal exudates increased dramatically. Elevated luciferase expression was also detectable in peripheral blood and bone marrow CD11b(+) cells. Ex vivo stimulation of primary myeloid cells showed activation of the human extrapituitary promoter by TNF-α, lipopolysaccharide, or TG. These findings were confirmed in human peripheral blood monocytes, showing that the transgenic rat provided a faithful model for the human gene. Thus, the resolution of an inflammatory response is associated with dramatic activation of the PRL gene promoter in the myeloid lineage.


Subject(s)
Myeloid Cells/metabolism , Peritonitis/genetics , Prolactin/genetics , Transcription, Genetic , Animals , Bone Marrow Cells/metabolism , CD11b Antigen/metabolism , Cells, Cultured , Gene Expression/drug effects , Humans , Lipopolysaccharides/pharmacology , Luciferases/genetics , Luciferases/metabolism , Macrophages/metabolism , Microscopy, Fluorescence , Monocytes/metabolism , Neutrophils/metabolism , Peritonitis/chemically induced , Peritonitis/metabolism , Prolactin/metabolism , Rats , Rats, Transgenic , Regulatory Sequences, Nucleic Acid/genetics , Reverse Transcriptase Polymerase Chain Reaction , Thioglycolates/pharmacology , Thioglycolates/toxicity , Tumor Necrosis Factor-alpha/pharmacology
18.
Biochem Pharmacol ; 83(3): 355-67, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22138446

ABSTRACT

Hsp90 and topoisomerase I are both targets for chemotherapeutic agents. Topoisomerase I poisons are standard clinical treatments, whilst Hsp90 inhibitors are progressing through clinical trials. We have demonstrated that when an Hsp90 inhibitor and topoisomerase I poison are combined they produce a synergistic increase in apoptosis in both p53⁺/⁺ and p53⁻/⁻ HCT116 human colon cancer cells. Lack of p53 is associated with an increase in sensitivity to the combination treatment; p53⁺/⁺ cells treated with the topoisomerase I poison topotecan (TPT) arrest at G2, whereas in p53⁻/⁻ cells the additional presence of the Hsp90 inhibitor geldanamycin (GA) selectively abrogates the G2M checkpoint. More importantly we report that there is a common underlying p53-independent mechanism behind the observed synergistic combined drug effect. We show that concurrent treatment with GA and TPT is able to reverse TPT induced up-regulation of the anti-apoptotic protein Bcl2 in both p53⁺/⁺ and p53⁻/⁻ HCT116 cells. The data suggests that inhibition of Hsp90 mediates down-regulation of Bcl2 following the combination treatment and cause a synergistic increase in apoptosis in both p53⁺/⁺ and p53⁻/⁻ HCT116 cells; p53⁻/⁻ HCT116 cells are more sensitive to the treatment because they also fail to arrest at G2 in the cell cycle.


Subject(s)
Apoptosis Regulatory Proteins/antagonists & inhibitors , Cell Cycle Checkpoints/physiology , Cell Cycle Proteins/antagonists & inhibitors , Colonic Neoplasms/enzymology , DNA Topoisomerases, Type I/metabolism , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Apoptosis Regulatory Proteins/biosynthesis , Benzoquinones/administration & dosage , Cell Cycle Checkpoints/drug effects , Cell Cycle Proteins/biosynthesis , Colonic Neoplasms/drug therapy , Drug Therapy, Combination , HCT116 Cells , HSP90 Heat-Shock Proteins/metabolism , Humans , Lactams, Macrocyclic/administration & dosage , Topoisomerase I Inhibitors/administration & dosage
19.
J Cell Sci ; 124(Pt 20): 3484-91, 2011 Oct 15.
Article in English | MEDLINE | ID: mdl-21984812

ABSTRACT

Important questions in biology have emerged recently concerning the timing of transcription in living cells. Studies on clonal cell lines have shown that transcription is often pulsatile and stochastic, with implications for cellular differentiation. Currently, information regarding transcriptional activity at cellular resolution within a physiological context remains limited. To investigate single-cell transcriptional activity in real-time in living tissue we used bioluminescence imaging of pituitary tissue from transgenic rats in which luciferase gene expression is driven by a pituitary hormone gene promoter. We studied fetal and neonatal pituitary tissue to assess whether dynamic patterns of transcription change during tissue development. We show that gene expression in single cells is highly pulsatile at the time endocrine cells first appear but becomes stabilised as the tissue develops in early neonatal life. This stabilised transcription pattern might depend upon tissue architecture or paracrine signalling, as isolated cells, generated from enzymatic dispersion of the tissue, display pulsatile luminescence. Nascent cells in embryonic tissue also showed coordinated transcription activity over short distances further indicating that cellular context is important for transcription activity. Overall, our data show that cells alter their patterns of gene expression according to their context and developmental stage, with important implications for cellular differentiation.


Subject(s)
Gene Expression Regulation, Developmental , Periodicity , Pituitary Gland/embryology , Pituitary Hormones/metabolism , Animals , Animals, Genetically Modified , Animals, Newborn , Cells, Cultured , Cellular Microenvironment/genetics , Gene Expression Profiling , Luciferases, Firefly/genetics , Luminescent Measurements/methods , Morphogenesis/genetics , Pituitary Gland/metabolism , Pituitary Hormones/genetics , Promoter Regions, Genetic/genetics , Rats
20.
Obesity (Silver Spring) ; 17(5): 842-62, 2009 May.
Article in English | MEDLINE | ID: mdl-19396063

ABSTRACT

Rapid shifts in the demographics and techniques of weight loss surgery (WLS) have led to new issues, new data, new concerns, and new challenges. In 2004, this journal published comprehensive evidence-based guidelines on WLS. In this issue, we've updated those guidelines to assure patient safety in this fast-changing field. WLS involves a uniquely vulnerable population in need of specialized resources and ongoing multidisciplinary care. Timely best-practice updates are required to identify new risks, develop strategies to address them, and optimize treatment. Findings in these reports are based on a comprehensive review of the most current literature on WLS; they directly link patient safety to methods for setting evidence-based guidelines developed from peer-reviewed scientific publications. Among other outcomes, these reports show that WLS reduces chronic disease risk factors, improves health, and confers a survival benefit on those who undergo it. The literature also shows that laparoscopy has displaced open surgery as the predominant approach; that government agencies and insurers only reimburse procedures performed at accredited WLS centers; that best practice care requires close collaboration between members of a multidisciplinary team; and that new and existing facilities require wide-ranging changes to accommodate growing numbers of severely obese patients. More than 100 specialists from across the state of Massachusetts and across the many disciplines involved in WLS came together to develop these new standards. We expect them to have far-reaching effects of the development of health care policy and the practice of WLS.


Subject(s)
Bariatric Surgery/standards , Obesity/surgery , Weight Loss , Bariatric Surgery/adverse effects , Bariatric Surgery/methods , Evidence-Based Medicine/standards , Gastrectomy/methods , Gastric Bypass/methods , Health Policy , Humans , Massachusetts , Medicine , Obesity/mortality , Obesity/psychology , Patient Care Team , Patient Education as Topic , Patient Selection , Reimbursement Mechanisms , Risk Factors , Specialization , Survivors , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...